Pharmadrug Stock Profit Margin
| LMLLF Stock | USD 0.01 0 38.67% |
Pharmadrug fundamentals help investors to digest information that contributes to Pharmadrug's financial success or failures. It also enables traders to predict the movement of Pharmadrug Pink Sheet. The fundamental analysis module provides a way to measure Pharmadrug's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmadrug pink sheet.
Pharmadrug |
Pharmadrug Company Profit Margin Analysis
Pharmadrug's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Pharmadrug has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Pharmadrug Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmadrug's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharmadrug could also be used in its relative valuation, which is a method of valuing Pharmadrug by comparing valuation metrics of similar companies.Pharmadrug is currently under evaluation in profit margin category among its peers.
Pharmadrug Fundamentals
| Return On Equity | -0.59 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.08) % | |||
| Current Valuation | 4.43 M | |||
| Shares Outstanding | 355.63 M | |||
| Shares Owned By Insiders | 1.88 % | |||
| Price To Book | 0.55 X | |||
| Price To Sales | 7.86 X | |||
| Revenue | 494.99 K | |||
| Gross Profit | 182.04 K | |||
| EBITDA | (5.27 M) | |||
| Net Income | (5.63 M) | |||
| Cash And Equivalents | 126.38 K | |||
| Total Debt | 786.37 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 2.69 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (4.13 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 2.94 | |||
| Market Capitalization | 3.97 M | |||
| Total Asset | 19.52 M | |||
| Z Score | 3.0 | |||
| Net Asset | 19.52 M |
About Pharmadrug Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmadrug's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmadrug using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmadrug based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmadrug Pink Sheet
Pharmadrug financial ratios help investors to determine whether Pharmadrug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmadrug with respect to the benefits of owning Pharmadrug security.